EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 70 / Numéro 2 (Mars-Avril 2015) Therapie, 70 2 (2015) 197-202 Références
Numéro
Therapie
Volume 70, Numéro 2, Mars-Avril 2015
Addictovigilance : le défi pharmacologique de l'évaluation et de la prévention des substances à risque
Page(s) 197 - 202
Section Addictovigilance / Addictovigilance
DOI https://doi.org/10.2515/therapie/2015013
Publié en ligne 9 avril 2015
  1. Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side Effects. Prim Care Companion J Clin Psychiatry 2000; 2 (5): 159-64 [CrossRef] [PubMed] [Google Scholar]
  2. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003, 160(11): 1909-18 [CrossRef] [PubMed] [Google Scholar]
  3. Frances C, Hoizey G, Millart H, et al. Paediatric methylphenidate (Ritalin) restrictive conditions of prescription in France. Br J Clin Pharmacol 2004; 57: 115-6 [CrossRef] [PubMed] [Google Scholar]
  4. Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 2012; 107(3): 467-77 [CrossRef] [PubMed] [Google Scholar]
  5. Frauger E, Pauly V, Natali F, et al. Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS Drugs 2011 May 1; 25(5): 415-24 [CrossRef] [PubMed] [Google Scholar]
  6. Frauger E, Moracchini C, Le Boisselier R, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 2013 Dec; 27(6): 672-82 [CrossRef] [PubMed] [Google Scholar]
  7. Frauger E, Spadari M, Djezzar S, et al. Étude des pratiques d’injection intraveineuse et autres détournements du méthylphénidate (région Paca-Corse). Le Courrier des addictions 2011; 13: 15-20 [Google Scholar]
  8. Ehrhardt C, Boucherie Q, Pauly V, et al. Trends in methylphenidate dispensing from 2005 to 2011. Fundam Clin Pharmacol 2014; 28 (Suppl 1): 21 (A093) [Google Scholar]
  9. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). Méthylphénidate : données d’utilisation et de sécurité d’emploi en France. Juillet 2013 http://ansm.sante.fr/var/ansm_site/storage/original/application/8dd1277a3867155547b4dce58fc0db00.pdf Accessed December 24th, 2014 (26 pages) [Google Scholar]
  10. Treceño C, Martín Arias LH, Sáinz M, et al. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf 2012 Apr; 21(4): 435-41 [CrossRef] [PubMed] [Google Scholar]
  11. Trip AM, Visser ST, Kalverdijk LJ, et al. Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009 Apr; 67(4): 466-8 [CrossRef] [PubMed] [Google Scholar]
  12. Zoëga H, Furu K, Halldórsson M, et al. Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand 2011 May; 123(5): 360-7 [CrossRef] [PubMed] [Google Scholar]
  13. Pottegård A, Bjerregaard BK, Glintborg D, et al. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol 2013 Mar; 69(3): 589-98 [CrossRef] [PubMed] [Google Scholar]
  14. Lapeyre-Mestre M, Gony M, Carvajal A, et al. A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions. Eur Addict Res 2014; 20(4): 174-82 [CrossRef] [PubMed] [Google Scholar]
  15. Bruggisser M, Ceschi A, Bodmer M, et al. Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997-2009. Swiss Med Wkly 2010; 140: w13115 [PubMed] [Google Scholar]
  16. Bruggisser M, Bodmer M, Liechti M. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly 2011 Oct 9; 141: w13267 [PubMed] [Google Scholar]
  17. Livio F, Rauber-Lüthy C, Biollaz J, et al. Methylphénidate et abus. Paediatrica 2009; 20(5): 41-4 http://www.swiss-paediatrics.org/sites/default/files/paediatrica/vol20/n5/pdf/41-44.pdf Accessed December 24th, 2014 (4 pages) [Google Scholar]
  18. Bjarnadottir GD, Rafnar BO, Sigurdsson E, et al. Methylphenidate use among Icelandic i.v. substance abusers. European Psychiatry 2013; 28 (suppl 1): P703 [CrossRef] [Google Scholar]
  19. Geirs DP, Pottegård A, Halldórsson M, et al. A nationwide study of ADHD drug use among adults in Iceland 2003-2012. Basic Clin Pharmacol Toxicol 2014 Apr 1, DOI: 10.1111/bcpt.12243 [Google Scholar]
  20. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006; 54: 269-78 [CrossRef] [PubMed] [Google Scholar]
  21. Wright ER, Kooreman HE, Greene MS, et al. The iatrogenic epidemic of prescription drug abuse: county-level determinants of opioid availability and abuse. Drug Alcohol Depend 2014 May 1; 138: 209-15 [CrossRef] [PubMed] [Google Scholar]
  22. Le Lait MC, Martinez EM, Severtson SG, et al. Assessment of prescription opioid intentional exposures across the rural-urban continuum in the United States using both population and drug availability rates. Pharmacoepidemiol Drug Saf 2014 Dec; 23(12): 1334-7 [CrossRef] [PubMed] [Google Scholar]
  23. Swanson JM, Volkow ND. Increasing use of stimulants warns of potential abuse. Nature 2008; 453(7195): 586 [CrossRef] [Google Scholar]
  24. Micallef J, Star K, Palmaro A, et al.. Detection and magnitude of methylphenidate abuse and misuse using vigibase and correlation with level of use in Europe [poster, abstract]. Pharmacoepidemiol Drug Saf 2012; 21: 450 [CrossRef] [PubMed] [Google Scholar]
  25. Lapeyre-Mestre M, Sapède C, Moore N, et al. Pharmacoepidemiology studies: what levels of evidence and how can they be reached? Therapie 2013; 68(4): 241-52 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  26. Micaleff J, Jolliet P, Victorri-Vigneau C, et al. First meeting of the French CEIP (Centres d’Evaluation et d’Information sur la Pharmacodépendance). Assessment of the abuse and pharmacodependence potential during drug development. Therapie 2008; 63(1): 55-65 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  27. Daveluy A, Thirion X. Vigilance sanitaire et agences régionales de santé : quelle évaluation régionale du risque d’abus et d’abus et d’addiction aux stupéfiants et aux psychotropes ? La Lettre du Pharmacologue 2011; 25(2): 57-61 [Google Scholar]
  28. Moracchini C, Frauger E, Pauly V, et al. Harm reduction centers (“CAARUD”): privileged places for warning signal detection in addictovigilance. Therapie 2012; 67(5): 437-45 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  29. Nordmann S, Pradel V, Lapeyre-Mestre M, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician 2013 Jan; 16(1): 89-100 [PubMed] [Google Scholar]
  30. Brownstein JS, Green TC, Cassidy TA, et al. Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol Drug Saf 2010 Jun; 19(6): 627-37 [CrossRef] [PubMed] [Google Scholar]
  31. Micallef J, Pradel V, Thirion X, et al. Use of the health insurance database by the centres for evaluation and information on pharmacodependance: examples, interests and future prospects. Therapie 2004 Nov-Dec; 59(6): 581-8 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Begaud B, Costagliola D. Rapport sur la surveillance et la promotion du bon usage du médicament. Rapport Ministère des Affaires Sociales et de la Santé, 2013 http://www.sante.gouv.fr/IMG/pdf/Rapport_Begaud_Costagliola.pdf Accessed December 24th, 2014 (54 pages) [Google Scholar]
  33. Gahr M, Freudenmann RW, Hiemke C, et al. Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res 2014 Jan 30; 215(1): 252-4 [CrossRef] [PubMed] [Google Scholar]
  34. Organisation Mondiale de la Santé. Comité OMS d’experts de la pharmacodépendance. Série de rapports techniques 973. Trente-cinquième rapport, 2012 http://apps.who.int/iris/bitstream/10665/78615/1/WHO_TRS_973_fre.pdf Accessed December 24th, 2014 (39 pages) [Google Scholar]
  35. Karlstad O, Furu K, Skurtveit S, et al. Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway. Eur Addict Res 2013, 20(2): 59-65 [CrossRef] [PubMed] [Google Scholar]
  36. Pérez de Los Cobos J, Siñol N, Pérez V, et al. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol 2014; 77(2): 337-56 [CrossRef] [PubMed] [Google Scholar]
  37. INSERM. Expertises collectives. Medicaments psychotropes. Consommations et pharmacodépendances. 2012 http://www.inserm.fr/content/download/62753/417059/file/Medicaments-psychotropes-fascicule-corpus.pdf Accessed December 24th, 2014 (118 pages) [Google Scholar]
  38. Lapeyre Mestre M. Addiction médicamenteuse : quelles données pour évaluer et prévenir ? Psychotropes 2013; 19: 65-80 [CrossRef] [Google Scholar]